 PR Contact
Heidi Bullock
Director, Marketing
650.381.5150
|
|
Press Releases
|
|
Ingenuity Systems Chosen As Global Pathways Analysis Provider To AstraZeneca
Ingenuity Pathways Analysis is chosen after thorough evaluation of major pathway analysis
platforms.
REDWOOD CITY, CA - OCT. 24, 2006 - Ingenuity Systems announced a global licensing deal to
provide the central pathways analysis platform for AstraZeneca's global research and development
programs. Ingenuity Pathway Analysis (IPA) software was chosen after a comprehensive evaluation of
several major pathway analysis products.
"The need for pathways solutions is fundamental to our research and development efforts so for the
past year, seven AstraZeneca sites in three countries thoroughly tested leading pathway analysis
solutions based on stringent requirements," commented Adriano Henney, Director, Discovery Enabling
Capabilities and Sciences, AstraZeneca. "Ingenuity Pathways Analysis had superior depth and quality of
content and provided the most relevant functionality that was easy to use across multiple therapeutic
areas of interest. IPA was the considered choice to meet our needs."
"Pathways analysis is a fundamental part of most R&D processes and with the addition of AstraZeneca
as a customer, IPA is now used by all major pharmaceutical companies in the world," stated Jake
Leschly, President and Chief Executive Officer. "AstraZeneca has a strong commitment and vision for
pathways analysis and we look forward to partnering with them to enable and extend the use of IPA
into their global R&D programs."
Ingenuity Pathways Analysis is a software application that enables researchers to model, analyze and
understand the complex biological systems at the core of life science research. IPA is deployed in all
major pharmaceutical companies and hundreds of biotechnology companies and academic institutions
globally. It supports analysis of all high throughput analysis platforms and is used in virtually all areas
of drug discovery and development from target identification and validation to biomarkers, predictive
toxicology, and pharmacogenomics.
Ingenuity Pathways Analysis is available as a web-delivered, hosted, or deployed solution. Fully
functional complimentary trials are available at www.ingenuity.com/trial.
About Ingenuity SystemsŪ
Ingenuity enables researchers to model, analyze and understand complex biological systems
foundational to human health and disease. The Ingenuity products include pathways analysis software
and knowledge bases for biologists and bioinformaticians, and enterprise knowledge management
infrastructure, content and services for leading pharmaceutical and biotech companies. Ingenuity was
founded in 1998 and is headquartered in Redwood City, California with offices in Germany, Switzerland,
France, the United Kingdom, and Japan. www.ingenuity.com.
About AstraZeneca
AstraZeneca is a major international healthcare business engaged in the research, development,
manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is
one of the world's leading pharmaceutical companies with healthcare sales of $23.95 billion and leading
positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection
products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the
FTSE4Good Index.
Contact:
Holli Dickson
Account Supervisor
Porter Novelli Life Sciences
858.527.3495
|
Heidi Bullock
Director, Marketing
Ingenuity Systems
650.381.5150 |
> View as PDF  |
|
|
|
|
